Form 4: J&J EVP, CIO Swanson Exercises Options, Sells Shares

Johnson & Johnson's EVP and CIO, James D. Swanson, reported exercising stock options and converting equity awards, followed by sales to cover taxes and realize gains, while also receiving new equity grants.

Summary

• James D. Swanson, EVP and CIO of Johnson & Johnson (JNJ), engaged in multiple transactions involving JNJ common stock and derivative securities.
• On February 13, 2026, Swanson converted 447 Restricted Share Units (RSUs) and 9,412 Performance Share Units (PSUs) into common stock at a $0 exercise price.
• Also on February 13, 2026, Swanson exercised employee stock options for 19,368 shares at $165.89 and 22,191 shares at $162.75.
• Following these acquisitions, Swanson sold 19,368 shares at a weighted average price of $243.76 and 22,191 shares at a weighted average price of $243.71.
• Shares totaling 143 and 3,547 were withheld for tax payments upon the vesting of RSUs and PSUs, respectively, at a price of $244.55 per share.
• On February 15, 2026, Swanson converted 492 RSUs and 709 RSUs into common stock at a $0 exercise price.
• Shares totaling 214 and 309 were withheld for tax payments upon the vesting of RSUs at a price of $243.45 per share.
• Swanson was awarded 19,449 new employee stock options with an exercise price of $243.45 and 1,397 new Restricted Share Units on February 15, 2026.
• On February 17, 2026, Swanson exercised employee stock options for 20,521 shares at $164.62 and subsequently sold all 20,521 shares at a weighted average price of $242.7.
• Following all reported transactions, Swanson's direct beneficial ownership of Johnson & Johnson common stock stands at 25,698.131 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event. While there are significant sales, they are primarily linked to option exercises and tax obligations, which is routine. The executive also received new equity awards, indicating continued alignment with the company's future.

Positives

• The executive exercised a significant number of stock options, indicating the value of the company's equity compensation program.
• New awards of 19,449 employee stock options and 1,397 Restricted Share Units were granted, demonstrating continued incentive alignment with the company's long-term performance.

Negatives

• A substantial portion of the shares acquired through option exercises and RSU/PSU conversions were immediately sold, which could be interpreted as the executive realizing gains rather than increasing long-term holdings.
• Shares were withheld for tax payments, which is a common practice but reduces the number of shares directly held by the executive.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transaction reports like this Form 4 are routine disclosures in the U.S. equity markets. They provide transparency into executive compensation and personal investment activities, which can sometimes offer insights into management's perception of the company's value. For a large, established pharmaceutical and consumer health company like Johnson & Johnson, such transactions by a senior executive are generally viewed as standard compensation-related activity rather than a strong signal of future company performance.

Comparison to Industry Standards

• The exercise of stock options and subsequent sale of shares to cover taxes and realize gains is a common practice among executives in publicly traded companies across various industries, including healthcare and pharmaceuticals.
• The grant of new equity awards (RSUs and stock options) aligns with typical long-term incentive plans designed to retain key talent and align executive interests with shareholder value, comparable to practices at peers like Pfizer (PFE) or Merck (MRK).

Stakeholder Impact

• Shareholders: The transactions provide transparency into executive compensation and personal investment activities. The sales represent a minor increase in the float, but are unlikely to significantly impact the stock price.
• Employees: The continued granting of equity awards reinforces the company's long-term incentive plan structure for key personnel.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, including option exercises, RSU/PSU conversions, and subsequent sales to cover taxes and realize gains, alongside new equity grants. Such activity is common and generally does not provide a strong signal for a 'buy' or 'sell' recommendation for a large, stable company like Johnson & Johnson. The net impact on the executive's beneficial ownership is relatively stable, suggesting no significant change in investment thesis based solely on this filing. Therefore, a 'hold' recommendation is appropriate.

Keywords

Johnson & Johnson, JNJ, Insider Trading, Form 4, Stock Options, Restricted Share Units, Performance Share Units, Executive Compensation, Share Sale, Beneficial Ownership